Recent Company News

• 11:58 PM ET Oct 16, 2025
  

  SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

• 12:15 PM ET Oct 07, 2025
  

  SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders

• 11:14 AM ET Oct 06, 2025
  

  StreetAccount M&A Summary: Week of 29-Sep

• 08:07 AM ET Sep 30, 2025
  

  Barinthus Biotherapeutics to combine with Clywedog Therapeutics in all-stock transaction ($1.48, 0.00)

• 08:11 AM ET Aug 07, 2025
  

  Barinthus Biotherapeutics reports Q2 EPS ($0.52) vs FactSet ($0.33) [2 est, ($0.37)-(0.29)] ($1.31, 0.00)

• 08:21 AM ET May 07, 2025
  

  Barinthus Biotherapeutics terminates CFO Gemma Brown as part of restructuring plan; discloses new data on VTP-300 at EASL Congress - 8-K ($1.00, 0.00)

• 08:03 AM ET May 07, 2025
  

  Barinthus Biotherapeutics reports Q1 EPS ($0.49) vs FactSet ($0.36) [3 est, ($0.41)-(0.30)] ($1.00, 0.00)

• 07:25 AM ET Mar 20, 2025
  

  Barinthus Biotherapeutics reports FY EPS ($1.55) vs FactSet ($1.48) [3 est, ($1.67)-(1.32)] ($0.99, 0.00)

• 08:10 AM ET Jan 10, 2025
  

  Barinthus Biotherapeutics announces strategic focus in immunology and inflammation; provides financial update ($1.14, 0.00)

• 04:04 PM ET Nov 25, 2024
  

  Barinthus Biotherapeutics Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer ($0.98, 0.00)